331 related articles for article (PubMed ID: 22726096)
1. Personalized prophylaxis.
Collins PW
Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
[TBL] [Abstract][Full Text] [Related]
2. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
3. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
Collins PW; Fischer K; Morfini M; Blanchette VS; Björkman S;
Haemophilia; 2011 Jan; 17(1):2-10. PubMed ID: 20731726
[TBL] [Abstract][Full Text] [Related]
4. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
5. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
Shapiro AD; Korth-Bradley J; Poon MC
Haemophilia; 2005 Nov; 11(6):571-82. PubMed ID: 16236106
[TBL] [Abstract][Full Text] [Related]
6. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
7. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
8. Considerations in individualizing prophylaxis in patients with haemophilia A.
Valentino LA
Haemophilia; 2014 Sep; 20(5):607-15. PubMed ID: 24712891
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis in the haemophilia population.
Blanchette VS
Haemophilia; 2010 Jul; 16 Suppl 5():181-8. PubMed ID: 20590879
[TBL] [Abstract][Full Text] [Related]
10. Models of prophylaxis.
Berntorp E; Fischer K; Miners A
Haemophilia; 2012 Jul; 18 Suppl 4():136-40. PubMed ID: 22726097
[TBL] [Abstract][Full Text] [Related]
11. [Prophylaxis in patients with haemophilia complicated by inhibitors].
Paweł Ł
Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
[TBL] [Abstract][Full Text] [Related]
12. Importance of pharmacokinetics in the management of hemophilia.
Barnes C
Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
[TBL] [Abstract][Full Text] [Related]
13. Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia.
Thornburg CD; Pipe SW
Haemophilia; 2006 Mar; 12(2):198-9. PubMed ID: 16476098
[No Abstract] [Full Text] [Related]
14. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
Walsh CE; Valentino LA
Haemophilia; 2009 Sep; 15(5):1014-21. PubMed ID: 19493018
[TBL] [Abstract][Full Text] [Related]
15. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
16. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
Nagel K; Walker I; Decker K; Chan AK; Pai MK
Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
[TBL] [Abstract][Full Text] [Related]
17. The current status of prophylactic replacement therapy in children and adults with haemophilia.
Ljung R; Gretenkort Andersson N
Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
[TBL] [Abstract][Full Text] [Related]
18. Prevention of arthropathy in haemophilia: prophylaxis.
Santagostino E; Mancuso ME
Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
[TBL] [Abstract][Full Text] [Related]
19. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
Lissitchkov T; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañes M; Paez A
Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
[TBL] [Abstract][Full Text] [Related]
20. Changing paradigm of prophylaxis with longer acting factor concentrates.
Carcao M
Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
